Articles tagged with Leukemia
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers have identified potential new prognostic biomarkers and therapeutic targets for adult B-acute lymphoblastic leukemia. A study found that changes in the epigenetic code are linked to aggressive traits in the disease.
Researchers have developed a new technique to study how myeloids become white blood cells, providing new insights into the molecular mechanisms at work during this process. This approach offers potential improvements in treating myeloid diseases like leukemia by identifying key regulatory pathways and developing therapeutic strategies.
Scientists have developed a new video protocol to isolate brain tumor initiating stem cells from primary brain tumors, allowing for quick and efficient analysis of target cells. This approach has been effectively used to identify similar stem cells in leukemia patients.
Researchers at Northwestern University have identified two promising therapies to treat AMKL: alisertib and dimethylfasudil. Alisertib targets Aurora A kinase and shows promise in mouse models, while dimethylfasudil boosts mature bone marrow cells and inhibits malignant ones.
Researchers tested blood samples from 300 people for the presence of XMRV and pMLV genes, eliminating potential contamination that led to earlier false positives. No correlation between these viruses and chronic fatigue syndrome was found, refuting previous speculation.
Researchers at URMC have identified a new genetic signature for leukemia that can be used to target rogue cells. They found approximately 70 genes associated with the growth and survival of leukemia cells, opening up new avenues for drug discovery.
Researchers identified 38 prognostic subnetworks of interacting genes that predict cancer progression in chronic lymphocytic leukemia. The study helps define how CLL evolves over time, becoming more aggressive and deadly.
Researchers at the University of Cincinnati discovered a new gene target for leukemia therapy by inhibiting the protein Vav3, which controls cell signaling. This finding could lead to cellular targets for patients with BCR-ABL lymphoid leukemia, a type of leukemia with poor treatment outcomes.
A new study led by University of Rochester Medical Center researcher Barbara L. Asselin shows that giving a cardio-protective drug during cancer treatment may prevent damage to the hearts of childhood leukemia survivors. The study found that the drug Zinecard significantly reduced heart problems and damage in patients who received it.
Researchers at Ohio State University have identified a 'life-and-death' molecule on the surface of chronic leukemia cells that targets CD37. The finding could lead to more effective therapy for CLL, an as yet incurable cancer that occurs in over 16,000 Americans annually.
A study has found that high-throughput sequencing can detect minimal residual disease in nearly double the number of leukemia patients as current gold standard method. This technology offers a greater chance of survival by predicting disease relapse sooner.
Researchers discovered that 40% of LGL patients have a STAT3 mutation, which may aid in diagnosing and treating the disease. The mutation is also associated with an increased risk of rheumatoid arthritis, opening new avenues for understanding its pathogenesis.
A phase I/II clinical trial indicates that older patients with chronic lymphocytic leukemia respond well to the experimental drug ibrutinib, which has few side effects and a high one-year survival rate. The study suggests that ibrutinib deserves further testing as a first-line therapy for elderly CLL patients.
Researchers at UCSD School of Medicine identified G protein-coupled receptors as potential biomarkers and therapeutic targets for chronic lymphocytic leukemia. The expression of specific GPCRs, such as VIPR1, is linked to disease stage and prognosis.
Researchers have identified microRNA-155 as a molecule that controls the severity of acute graft-versus-host disease in leukemia patients who receive bone-marrow transplants. Reducing or blocking miR-155 expression decreases GVHD severity and increases survival, suggesting a new strategy for treating the condition.
A team of researchers at Case Western Reserve University School of Medicine has developed a new theranostic agent for the treatment of acute lymphoblastic leukemia (ALL). The agent combines a diagnostic test with targeted therapy to provide personalized treatments for pediatric leukemia.
Yale researchers found that megakaryocytes grow 10-15 times larger than other blood cells through endomitosis, but a malfunction in this process may lead to leukemia. The discovery reveals the formation of functional platelets and provides clues about what may go awry to transform normal megakaryocytes into malignant leukemia cells.
A study in a mouse model of Down syndrome identifies increased expression of protein Dyrk1a as a promoter of acute megakaryoblastic leukemia, offering a candidate therapeutic target for treatment.
Research identifies increased expression of Dyrk1a as a potential explanation for the increased risk of acute megakaryoblastic leukemia (AMKL) in children with Down syndrome. A candidate therapeutic target, small-molecule inhibitors of DYRK1A activity, have been proposed.
Research identifies SIRT1 as a key enzyme protecting leukemia stem cells from stress and driving cancer recurrence. Inhibiting SIRT1 selectively reduces CML stem cell survival and growth, offering a potential therapeutic target for treatment resistance.
Researchers at URMC discovered a link between leukemia cells and bone formation, finding that leukemia alters the balance of osteoblast and osteoclast activity. The study suggests that targeting osteoclasts could be a potential treatment strategy for leukemia.
Researchers found that blocking HSP90 activity renders protected proteins vulnerable to destruction, slowing the growth of MIF-expressing breast tumors. HSP90 inhibitors also showed promise in slowing leukemia cell growth driven by hyperactive JAK2 enzyme versions.
A team of researchers identified genetic mutations in OATP1B1 and OATP1B3 as the cause of Rotor syndrome, a rare genetic disorder characterized by jaundice. Complete deficiency of these proteins causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.
A Penn State research team has discovered a compound produced from fish oil that targets and kills leukemia stem cells, potentially leading to a cure for the disease. The compound, D12-PGJ3, selectively activates a gene in leukemia stem cells that programs their own death.
Researchers discovered nine frequently mutated genes in CLL that may help predict disease progression and guide treatment. The study identified new cancer pathway aberrant RNA splicing, which could lead to novel targeted treatments.
A phase Ib/II clinical trial reveals that PCI-32765 is highly active and well-tolerated in 61 relapsed CLL patients, with 70% achieving complete or partial remission after 10 months of treatment. The agent targets Bruton's tyrosine kinase, a key protein for CLL-cell survival.
A study published in Blood has identified a potential marker, PD-1, that is more frequently found in young leukemia patients who experience relapses. This discovery could lead to the development of simple tests to predict relapse, reducing the risk for these vulnerable individuals.
Researchers at Princess Margaret Cancer Program have identified a promising approach to treating leukemia using the antibiotic tigecycline. By cutting off energy production in leukemia stem cells, the drug can selectively destroy these cancerous cells while sparing healthy ones.
Researchers have identified a gene variant associated with an increased risk of leukemia relapse in young patients treated with E. coli asparaginase, a common chemotherapy drug. This discovery may lead to personalized treatment approaches based on genetic profiles.
Scientists at Ohio State University have created a technique called nanochannel electroporation (NEP) that allows for precise injection of genes and proteins into individual cells. The method uses electrical pulses to deliver therapeutic agents, with potential applications in cancer diagnosis and treatment.
A new drug combination of fludarabine and alemtuzumab significantly increases progression-free survival and prolongs the lives of patients with chronic lymphocytic leukemia (CLL). The treatment spares patients from toxicities and offers a more convenient dosing schedule.
A newly identified DNA repair defect may leave some young leukemia patients less likely to benefit from chemotherapy, increasing the risk of relapse. The study found low levels of a key protein and missing regulatory genes in leukemia cells, suggesting a potential new marker for high-risk patients.
Researchers have found that Fasudil, a vasodilator used to treat cardiovascular problems, can slow the growth of leukemia cells by blocking the activity of Rho kinase. The study showed promising results in laboratory tests and extended survival in mice with leukemia.
A group of mutations in the interleukin-7 receptor gene have been identified in T-cell acute lymphoblastic leukemia patients, leading to uncontrolled cell proliferation. Researchers found that certain pharmaceutical drugs already in clinical use can eliminate these cells, providing a potential therapeutic approach against leukemia.
Scientists found that high levels of insulin-like growth factor 1 receptor (IGF1R) expression are required for leukemia-initiating cell activity in T-cell acute lymphoblastic leukemia (T-ALL). Blocking IGF1R using inhibitors or reducing its expression significantly impaired leukemia stem cells' self-renewal capacity.
Research suggests that blood stem cells may play a role in the development of chronic lymphocytic leukemia (CLL), a cancer of mature white blood cells. CLL often begins with an asymptomatic proliferation of B cells called monoclonal B lymphocytosis (MBL). The study found that hematopoietic stem cells, which can give rise to any type of...
A UT Southwestern men's support group has published a book to reach out to husbands and partners of women with cancer. The book shares stories of five men who know firsthand what it's like to love and care for a cancer patient, offering emotional support and practical advice.
Researchers at the University of Western Ontario identified two key genes, PU.1 and Spi-B, that appear essential in preventing B cell ALL, the most common form of ALL in children. The study found these genes function as unanticipated 'tumor suppressor' genes that prevent leukemia.
Researchers have discovered new gene mutations in CLL patients, linking NOTCH1 pathway to poorer prognosis and shorter survival. The findings suggest the potential for diagnostic and therapeutic purposes in human CLL.
The National Institutes of Health has signed a research and development agreement with two non-profit organizations to develop potential clinical therapies for rare blood cancers. The collaboration aims to bridge the gap between basic research and human testing, with the goal of accelerating the delivery of improved therapies to patients.
A study published in Nature shows that a combination therapy of RI-BPI and Gleevec eradicates cancer in cell and animal studies, targeting the Philadelphia chromosome-positive (Ph+) form of acute lymphoblastic leukemia (ALL). This breakthrough offers new hope for improved survival rates for children with this aggressive cancer.
A phase II study by the University of Texas M. D. Anderson Cancer Center found that an antibody-guided chemotherapy drug eradicated or greatly reduced ALL cells in 61% of patients with resistant or recurrent disease. This makes it a potential most active single-agent therapy for ALL.
Ray Johnston, a former NBA player, has survived acute promyelocytic leukemia thanks to experimental drug tamibarotene, which induced cancer cells to differentiate into mature cells. The rare form of leukemia is typically curable with current therapies but becomes more resistant and harder to treat upon relapse.
Researchers at UCSF have identified BCL6, a protein that leukemia cells use to survive treatment, as the basis for drug resistance. Targeting this protein may lead to more powerful cancer drugs and improved cure rates for children with leukemia.
Researchers identified previously undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia (T-ALL) using zebrafish models. These genetic characteristics can predict which patients are more likely to experience aggressive forms of the disease that recur after treatment or do not respond to therapy.
Cancer cells that reign during leukemia relapses have distinct DNA profiles compared to those at diagnosis. These mutated cells exhibit aggressive behavior in mice, suggesting a possible link between human and mouse models.
Researchers identified a potential new treatment for juvenile myelomonocytic leukemia, a rare form of childhood leukemia. The experimental drug, known as a MEK inhibitor, alleviated symptoms and delayed disease progression in mouse models.
Patients with CML taking imatinib in remission after two years have a mortality rate similar to the general population. Despite side effects, survival rates remain high even after eight years of treatment.
St. Jude researchers found that 18.3% of relapsed childhood acute lymphoblastic leukemia (ALL) patients had alterations in the CREBBP gene, compared to just 1% in non-relapsed patients. The study suggests that CREBBP mutations may be a potential indicator of relapse risk.
Researchers identified a small subset of NKT cells in normal white blood cells that give rise to rare large granular lymphocyte leukemia. Targeting interleukin-15 signaling and NKp46 may offer a new way to prevent this leukemia.
Researchers have created a bioengineered protein called CD19-L that selectively targets and destroys leukemia cells, including those resistant to chemotherapy. This breakthrough discovery offers new hope for treating childhood leukemia.
A study published in JAMA reveals that chromosome changes disrupt a molecular network influencing CLL outcome, providing new targets for treatment. Patients with 13q deletion generally have better prognosis than those with 11q or 17p deletions.
Researchers found that leukemia cells composed of multiple families of genetically distinct cells exist, leading to a re-evaluation of cancer progression and treatment strategies. The study's findings have positive implications for tailoring therapies to individual patients.
A Ph.D. student at Université du Québec à Montréal has identified a gene that may facilitate the diagnosis of B-cell acute lymphocytic leukemia, mostly affecting children. The Fmn2 gene shows abnormal activity in both mouse and human cells with this disease.
Researchers found that CLL patients with insufficient vitamin D levels progressed faster, were twice as likely to die, and had shorter survival times. Vitamin D supplements may offer a way to slow leukemia progression.
Researchers at IRCM identified a mechanism regulating activation-induced deaminase, which could lead to new therapies for some types of lymphoma and leukemia. The discovery found that Hsp90 inhibition destabilizes AID, preventing uncontrolled gene mutation and accelerating disease progression.
Researchers found that BAFF interacts with c-MYC gene, promoting aggressive leukemias and lymphomas. High levels of BAFF in CLL microenvironment may lead to improved treatment options by blocking its effects or inhibiting signaling pathways.
Researchers at Children's Hospital Los Angeles have discovered a way to overcome radiation resistance in leukemia cells by targeting the SYK tyrosine kinase molecular target. This breakthrough could improve treatment outcomes for children with relapsed leukemia, who currently face poor survival rates.
Researchers at IRCM discover a protein called Gfi1b that regulates blood stem cell activity and mobilization, potentially accelerating the production of new blood cells. This breakthrough could lead to more efficient and safer stem cell therapy for leukemia patients.
Researchers find a crucial protein involved in immune response also plays a role in T-cell acute lymphoblastic leukemia (T-ALL) progression. Suppressing the protein's activity eliminates leukemic cells, paving the way for potential new treatments.